BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...
In a recent study published in Nature Metabolism, researchers conducted clinical studies on murine animals and humans to evaluate the impact of high protein intake on the amino acid-mammalian target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results